The Immunology TA, led by Dr. Sue Dillon, is passionate about discovering new, transformational medicines to combat complex immunological diseases - rheumatoid arthritis, inflammatory bowel disease, psoriasis and pulmonary diseases, including asthma, COPD and other inflammatory lung diseases with high unmet need.
Building on a rich heritage of innovation in monoclonal antibody therapeutics for immunologic diseases, and expanding to oral and inhaled medicines for immunologic and pulmonary diseases, the Immunology TA strives to develop and deliver differentiated solutions that transform lives and bring hope to people living with chronic inflammatory diseases.
The Immunology Therapeutic Area (TA) has a strong history of innovation in monoclonal antibody therapeutics and continues to build a pipeline of new biologic products. We are also expanding into small-molecule oral medications and broadening our disease focus in autoimmune, inflammatory and pulmonary diseases. And with the acquisition of RespiVert announced in June 2010, the Immunology TA strengthened its pulmonary capabilities with the addition of an expert scientific team and potential for a new class of inhaled medicines.
In addition, we have a broad biomarker discovery program that should further the understanding of disease pathogenesis, or how a disease develops and progresses. We are also developing co-diagnostics to predict a patient's response to a drug in advance of treatment, therefore enabling better outcomes for patients.
We have established our leadership in Immunology through the development of innovative therapeutics that are focused on immune-mediated diseases with significant unmet needs such as inflammatory bowel disease (IBD), which includes Crohn's disease and ulcerative colitis, RA, ankylosing spondylitis, psoriatic arthritis and psoriasis. An estimated 1 in 6 people in the U.S. suffer from such chronic immune-mediated diseases, each of which can be debilitating and result in serious co-morbidities, while negatively impacting an individual's quality of life and ability to function.